Sigrid Nikol
Overview
Explore the profile of Sigrid Nikol including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
1055
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Norgren L, Weiss N, Nikol S, Lantis J, Patel M, Hinchliffe R, et al.
Br J Surg
. 2024 Jan;
111(2).
PMID: 38294084
Background: Revascularization is the primary treatment modality for chronic limb-threatening ischaemia (CLTI), but is not feasible in all patients. PLX-PAD is an off-the-shelf, placental-derived, mesenchymal stromal cell-like cell therapy. This...
2.
Fitridge R, Chuter V, Mills J, Hinchliffe R, Azuma N, Behrendt C, et al.
Diabetes Metab Res Rev
. 2023 Sep;
40(3):e3686.
PMID: 37726988
Diabetes related foot complications have become a major cause of morbidity and are implicated in most major and minor amputations globally. Approximately 50% of people with diabetes and a foot...
3.
Fitridge R, Chuter V, Mills J, Hinchliffe R, Azuma N, Behrendt C, et al.
J Vasc Surg
. 2023 Sep;
78(5):1101-1131.
PMID: 37724985
Diabetes related foot complications have become a major cause of morbidity and are implicated in most major and minor amputations globally. Approximately 50% of people with diabetes and a foot...
4.
Fitridge R, Chuter V, Mills J, Hinchliffe R, Azuma N, Behrendt C, et al.
Eur J Vasc Endovasc Surg
. 2023 Sep;
66(4):454-483.
PMID: 37724984
Diabetes related foot complications have become a major cause of morbidity and are implicated in most major and minor amputations globally. Approximately 50% of people with diabetes and a foot...
5.
Chuter V, Schaper N, Mills J, Hinchliffe R, Russell D, Azuma N, et al.
Diabetes Metab Res Rev
. 2023 Aug;
40(3):e3700.
PMID: 37539634
Introduction: Peripheral artery disease (PAD) is associated with an increased likelihood of delayed or non-healing of a diabetes-related foot ulcer, gangrene, and amputation. The selection of the most effective surgical...
6.
Chuter V, Schaper N, Hinchliffe R, Mills J, Azuma N, Behrendt C, et al.
Diabetes Metab Res Rev
. 2023 Jul;
40(3):e3701.
PMID: 37493206
Introduction: The presence of peripheral artery disease (PAD) confers a significantly increased risk of failure to heal and major lower limb amputation for people with diabetes-related foot ulcer (DFU). Determining...
7.
Chuter V, Schaper N, Mills J, Hinchliffe R, Russell D, Azuma N, et al.
Diabetes Metab Res Rev
. 2023 Jul;
40(3):e3683.
PMID: 37477087
As a progressive disease process, early diagnosis and ongoing monitoring and treatment of lower limb peripheral artery disease (PAD) is critical to reduce the risk of diabetes-related foot ulcer (DFU)...
8.
Geisler T, Branch K, Nikol S
Eur Heart J Case Rep
. 2022 Jul;
6(7):ytac201.
PMID: 35854882
Background: Dual pathway inhibition (DPI) with rivaroxaban 2.5 mg twice daily plus aspirin has demonstrated reductions in major adverse cardiovascular and limb events in eligible patients with chronic coronary artery...
9.
Weissler E, Aboyans V, Bauersachs R, Brodmann M, Nikol S, Debus S, et al.
JACC Cardiovasc Interv
. 2021 Apr;
14(7):796-802.
PMID: 33826501
Evidence for antithrombotic treatment following lower extremity revascularization (LER) for peripheral artery disease (PAD) is limited, leading to weak and conflicting guideline recommendations and heterogeneous practice patterns. This variability in...
10.
Weissler E, Jones W, Desormais I, Debus S, Mazzolai L, Espinola-Klein C, et al.
Atherosclerosis
. 2020 Nov;
315:10-17.
PMID: 33190107
Background And Aims: Polyvascular disease (PVD) affects approximately 20% of patients with atherosclerosis and is a strong independent risk factor for ischemic outcomes. However, guidelines do not address screening or...